Comparative Pharmacology
Head-to-head clinical analysis: DURYSTA versus MISOPROSTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURYSTA versus MISOPROSTOL.
DURYSTA vs MISOPROSTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaglandin analog; selective FP receptor agonist that increases uveoscleral outflow of aqueous humor.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
One intracameral implant (10 mcg) administered in the study eye by a qualified ophthalmologist. A second administration may be performed if necessary, at least 3 months after the initial implant.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine."
Clinical Note
moderateBalsalazide + Misoprostol
Not applicable due to local ocular administration with minimal systemic exposure; bimatoprost systemic half-life is approximately 45 minutes after intravenous administration.
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Minimal systemic absorption; no data on specific routes of elimination; expected to be primarily excreted via renal and biliary routes in small amounts.
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Category C
Category D/X
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide."